Stripe and Advent have made a $53B bid for PayPal, lifting PYPL shares and putting fintech ETFs like PYPU, FINX and IPAY in the spotlight.
Intuit (INTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does M&T Bank Corporation (MTB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does National Energy Services Reunited (NESR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Interactive Brokers Group, Inc. (IBKR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Acumen Pharmaceuticals (ABOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does Valero Energy (VLO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Pharvaris N.V. (PHVS) have what it takes to be a top stock pick for momentum investors?
Does Targa Resources, Inc. (TRGP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cummins (CMI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Fortinet (FTNT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Does Recruit Holdings Co., Ltd. (RCRUY) have what it takes to be a top stock pick for momentum investors?
Figs (FIGS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does Calumet, Inc. (CLMT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Gentex (GNTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sana (SANA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Atmus Filtration (ATMU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cytokinetics (CYTK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Immuneering (IMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Dell Technologies (NYSE:DELL | DELL Price Prediction) and Super Micro Computer (NASDAQ:SMCI) both reported earnings recently, and their results reveal two very different versions of the AI server story.
The decline leaves investors who bought into the company at the IPO price sitting on paper losses for the first time, potentially testing confidence in the stock.
The 175 MW contract creates a long revenue path while funding terms remain undisclosed and missed milestones may reduce rent or end the lease.
HON's Process Automation business faces pressure from weaker catalyst shipments and project delays, but order growth and its new automation focus offer support.
CTAS tops Q4 estimates on strong organic growth and record margins while issuing fiscal 2027 guidance that excludes the pending UniFirst acquisition.
LUV's Q2 revenues are likely to benefit from resilient travel demand and improved pricing power, with rising labor costs acting as the key challenge.
On July 27, AstraZeneca PLC will report its results for the second quarter of 2026. As a reminder, its revenue rose 12.5% year-over-year to $15.29 billion in Q1. Enhertu, one of the key growth drivers of AstraZeneca's oncology franchise, generated $831 million in revenue in Q1, up 39.4% YoY and 4.1% QoQ.
The trading week continues to advance and, for now, the Canadian dollar has started to lose the strength it had shown in prev.
The American currency pulled back as PPI report missed analyst estimates.
SpaceX (SPCX) stock fell below its initial public offering price on Wednesday, marking the lowest level since the company's market debut as enthusiasm surrounding one of the year's largest listings continued to fade. The stock declined around 2% to $133.34, falling below its $135 IPO price set during last month's record $86 billion offering.
Camurus AB (publ) (CAMRF) Q2 2026 Earnings Call Transcript